Energy And Commerce Members Want FDA Overseas Operations Update
This article was originally published in The Rose Sheet
Executive Summary
The GAO will report on foreign office closures and risk-based inspection policy amid Energy and Commerce leaders' concerns that an unequal playing field remains between domestic and foreign drug manufacturers.
You may also be interested in...
GDUFA II: Inspection Information Takes Center Stage
Sponsors say transparency is important as generic drug user fee negotiations move to inspection policy.
FDA Field Operations Would Endure Reductions Under Budget
President Obama’s FY 2016 blueprint includes cuts to ‘low-priority’ enforcement, surveillance and other activities in FDA human drugs and biologics programs, but still increases those operations overall.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.